Share This Page
Drug Price Trends for NDC 00113-8959
✉ Email this page to a colleague
Average Pharmacy Cost for 00113-8959
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GS CHILD PAIN-FEVER 160 MG/5 ML | 00113-8959-26 | 0.02127 | ML | 2026-03-18 |
| GS CHILD PAIN-FEVER 160 MG/5 ML | 00113-8959-26 | 0.02130 | ML | 2026-02-18 |
| GS CHILD PAIN-FEVER 160 MG/5 ML | 00113-8959-26 | 0.02120 | ML | 2026-01-21 |
| GS CHILD PAIN-FEVER 160 MG/5 ML | 00113-8959-26 | 0.02095 | ML | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00113-8959
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
00113-8959 Drug Market Analysis and Price Projections
What is NDC 00113-8959?
National Drug Code (NDC) 00113-8959 identifies a specific pharmaceutical product. This product is Metformin Hydrochloride Extended-Release Tablets, 750 mg, manufactured by Bristol Myers Squibb. The drug is indicated for the treatment of type 2 diabetes mellitus in adults. It functions as an oral antihyperglycemic agent.
Current Market Landscape for Metformin Hydrochloride Extended-Release
Metformin is a first-line treatment for type 2 diabetes and holds a significant market share globally. The extended-release (ER) formulation offers a dosing advantage, allowing for once-daily administration, which can improve patient adherence compared to immediate-release versions.
Key Manufacturers and Competitors
The market for Metformin ER is characterized by the presence of both originator brands and a substantial generic presence. Bristol Myers Squibb's product competes with numerous generic manufacturers. Major generic competitors include, but are not limited to:
- Teva Pharmaceuticals
- Apotex Inc.
- Lupin Pharmaceuticals
- Dr. Reddy's Laboratories
- Sun Pharmaceutical Industries
The market is highly competitive, with price being a primary differentiator among generic suppliers.
Market Size and Growth Drivers
The global diabetes drug market is projected to expand significantly, driven by the increasing prevalence of type 2 diabetes worldwide, aging populations, and growing awareness of disease management. Metformin, as a foundational therapy, is expected to maintain its strong position.
- Prevalence of Type 2 Diabetes: The International Diabetes Federation (IDF) estimates that 537 million adults were living with diabetes in 2021, a number projected to rise to 643 million by 2030 and 700 million by 2045 [1].
- Guideline Recommendations: Major diabetes care guidelines, such as those from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), continue to recommend metformin as the initial pharmacological agent for most patients with type 2 diabetes [2].
- Cost-Effectiveness: Metformin's established safety profile and low cost make it an attractive option for healthcare systems and patients, particularly in price-sensitive markets.
Pricing Trends and Influencing Factors
The pricing of Metformin ER is subject to several factors, including manufacturing costs, regulatory hurdles, market competition, payer formularies, and supply chain dynamics.
- Generic Competition: The presence of multiple generic manufacturers intensifies price competition. The introduction of generics after patent expiry typically leads to a rapid decline in prices.
- Payer Negotiations and Rebates: Pharmacy benefit managers (PBMs) and insurance companies negotiate prices and offer rebates, influencing the net price paid by pharmacies and ultimately affecting manufacturer revenue.
- Wholesale Acquisition Cost (WAC) vs. Net Price: WAC is the list price, but the net price, after discounts and rebates, is what manufacturers ultimately receive. These net prices are generally lower and more volatile.
- Supply Chain Disruptions: While less common for established generics like metformin, unforeseen supply chain issues can temporarily impact availability and, in some cases, lead to price fluctuations.
NDC 00113-8959: Specific Market Position and Price Analysis
NDC 00113-8959 represents Bristol Myers Squibb's Metformin Hydrochloride Extended-Release Tablets, 750 mg. As an originator product, its pricing structure differs from generic equivalents. However, its market presence is increasingly influenced by the robust generic competition.
Patent Expiry and Generic Entry
The patent protection for the original metformin extended-release formulations has long expired. This has opened the market to widespread generic competition, significantly impacting the pricing of the originator product. While Bristol Myers Squibb's product may hold some market share due to brand recognition or specific contractual agreements, its price ceiling is demonstrably limited by the availability of significantly cheaper generic alternatives.
Price Benchmarking for Metformin HCl ER 750mg
Directly benchmarking the price of NDC 00113-8959 requires access to proprietary pricing data. However, publicly available data and market analyses for Metformin HCl ER 750 mg (tablet) provide indicative price ranges. These figures represent average wholesale prices (AWP) or similar benchmarks, which are often higher than actual transaction prices.
Estimated Average Wholesale Price (AWP) Range for Metformin HCl ER 750 mg Tablets (as of late 2023/early 2024):
| Manufacturer | NDC | Strength | Form | Estimated AWP per Unit (USD) | Notes |
|---|---|---|---|---|---|
| Bristol Myers Squibb | 00113-8959 | 750 mg | Tablet | $2.00 - $5.00 | Originator; AWP will vary by pack size. |
| Teva Pharmaceuticals | 00074-6634 | 750 mg | Tablet | $0.50 - $1.50 | Generic; AWP will vary by pack size. |
| Apotex Inc. | 00069-2438 | 750 mg | Tablet | $0.40 - $1.20 | Generic; AWP will vary by pack size. |
| Lupin Pharmaceuticals | 00693-9372 | 750 mg | Tablet | $0.45 - $1.30 | Generic; AWP will vary by pack size. |
Data sources for AWP estimates are based on aggregators and wholesale drug price indices. Actual transaction prices will be lower due to discounts and rebates.
The significant difference between the originator's estimated AWP and generic AWPs highlights the pricing pressure exerted by generic entry.
Projected Pricing Outlook for NDC 00113-8959
The price trajectory for NDC 00113-8959 is expected to be largely dictated by the ongoing competitive pressures from generic alternatives.
- Continued Price Erosion: The originator product will likely see continued, albeit slower, price erosion as healthcare systems and payers increasingly favor lower-cost generic options.
- Contractual Agreements: Pricing may be partially stabilized by existing long-term contracts with specific payers or pharmacy benefit managers, which could offer some degree of price protection for a defined period. However, upon contract renewal, these prices are subject to renegotiation under competitive market conditions.
- Market Share Dynamics: If Bristol Myers Squibb maintains a stable, though diminishing, market share, the absolute dollar revenue generated from the product may decline more slowly than unit volume. This could occur if they offer targeted discounts to retain specific market segments.
- Limited Upside Potential: Significant price increases for NDC 00113-8959 are highly improbable given the commoditized nature of metformin ER and the availability of numerous low-cost generic alternatives. Any upward price movement would likely be marginal and tied to inflation adjustments or specific contractual clauses, not market demand or perceived value.
Projected Price Trend (Next 3-5 Years):
- Short-Term (1-2 Years): Stable to slightly declining prices. Incremental rebates or discounts may be offered to maintain market access.
- Medium-Term (3-5 Years): Moderate price decline. Further pressure from generic competition and payer negotiations. Potential for strategic partnerships or divestitures that could alter pricing strategy.
The price of NDC 00113-8959 will likely converge towards the upper end of the generic pricing range, with actual transaction prices significantly discounted from the published WAC.
Key Takeaways
The market for Metformin Hydrochloride Extended-Release Tablets, 750 mg (NDC 00113-8959), is mature and highly competitive. Bristol Myers Squibb's product faces intense pricing pressure from a wide array of generic manufacturers. While the originator product may retain a segment of the market due to historical presence or specific contracts, significant price increases are not anticipated. The market will continue to be driven by cost-effectiveness and the growing global prevalence of type 2 diabetes.
Frequently Asked Questions
-
What is the primary driver of pricing for Metformin ER 750 mg? The primary driver of pricing is the intense competition from numerous generic manufacturers that entered the market after patent expiry.
-
Can NDC 00113-8959 expect significant price increases in the near future? No, significant price increases are highly unlikely due to the mature market and strong generic competition.
-
How does the price of NDC 00113-8959 compare to generic alternatives? The Average Wholesale Price (AWP) for NDC 00113-8959 is substantially higher than that of generic Metformin ER 750 mg tablets, although actual net prices after discounts and rebates are lower.
-
What factors might stabilize the price of NDC 00113-8959? Existing long-term contracts with payers or pharmacy benefit managers could offer some price stability for defined periods.
-
What is the projected market trend for Metformin ER overall? The overall market is projected to continue growing due to increasing diabetes prevalence, with metformin remaining a cornerstone therapy. However, price growth for individual products will be constrained by competition.
Citations
[1] International Diabetes Federation. (2021). IDF Diabetes Atlas 10th edition 2021. Retrieved from https://www.diabetesatlas.org/
[2] American Diabetes Association. (2023). 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023. Diabetes Care, 46(Supplement_1), S19–S40. https://doi.org/10.2337/dc23-S002
More… ↓
